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Abstract
Pancreatic stellate cells (PSCs) play a crucial role in the aggressive behavior of pancreatic cancer. Although heterogeneity of
PSCs has been identified, the functional differences remain unclear. We characterized CD271+ PSCs in human pancreatic
cancer. Immunohistochemistry for CD271 was performed for 31 normal pancreatic tissues and 105 pancreatic ductal
adenocarcinomas (PDACs). We performed flow cytometry and quantitative RT-PCR, and assessed CD271 expression in PSCs
isolated from pancreatic tissues and the changes in CD271 expression in PSCs cocultured with cancer cells. We also
investigated the pattern of CD271 expression in a SCID mouse xenograft model. In the immunohistochemical analyses, the
CD271-high staining rates in pancreatic stroma in normal pancreatic tissues and PDACs were 2/31 (6.5%) and 29/105
(27.6%), respectively (p = 0.0069). In PDACs, CD271+ stromal cells were frequently observed on the edge rather than the
center of the tumors. Stromal CD271 high expression was associated with a good prognosis (p = 0.0040). Flow cytometric
analyses demonstrated CD271-positive rates in PSCs were 0–2.1%. Quantitative RT-PCR analyses revealed that CD271 mRNA
expression was increased in PSCs after coculture with pancreatic cancer cells. However, the level of CD271 mRNA expression
subsequently decreased after the transient increase. Furthermore, CD271 mRNA expression was decreased in PSCs
migrating toward pancreatic cancer cells through Matrigel. In the xenograft model, CD271+ PSCs were present at tumor
margins/periphery and were absent in the tumor core. In conclusion, CD271 was expressed in PSCs around pancreatic
tumors, but not in the center of the tumors, and expression decreased after long coculture with pancreatic cancer cells or
after movement toward pancreatic cancer cells. These findings suggest that CD271+ PSCs appear at the early stage of
pancreatic carcinogenesis and that CD271 expression is significantly correlated with a better prognosis in patients with
PDAC.
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Introduction
Pancreatic cancer is one of the most lethal cancers, and its 5-
year survival rate is only 4% [1]. It is characterized by excessive
desmoplasia, which plays a crucial role in its aggressive behavior
[2,3]. Recently, research on cancer biology has focused on cancer–
stroma interactions. Interactions between cancer cells and stromal
tissues are essential for the development and progression of tumors
[4]. Therapies targeting cancer–stroma interactions may represent
a new approach for the control of pancreatic cancer.
Pancreatic stellate cells (PSCs) have been identified as the
principal source of the excessive extracellular matrix observed in
chronic pancreatitis and pancreatic adenocarcinoma [5,6]. Similar
to hepatic stellate cells, an important cell type for extracellular
matrix production in hepatic fibrosis, PSCs store fat droplets
containing vitamin A within their cytoplasm [7]. PSCs become
activated upon stimulation by various autocrine or paracrine
factors. They express a-smooth muscle actin (a-SMA) and produce
various extracellular matrix proteins [8,9]. Soluble factors secreted
by activated PSCs promote the proliferation, migration, invasion,
and survival of pancreatic cancer cells against gemcitabine therapy
[10]. Thus, PSCs play an important role in cancer–stroma
interactions in pancreatic cancer.
Several reports suggest that stromal cells, such as myofibroblasts
and mesenchymal cells, isolated from various human tissues
exhibit different phenotypes [11,12]. We previously reported that
CD10+ PSCs enhance the progression of pancreatic cancer cells
[13]. These observations indicate that PSCs have functional
heterogeneity and further suggest that PSCs may contain several
other cell subpopulations that individually or synergistically affect
the progression of pancreatic cancer. Detailed characterization of
the PSCs in pancreatic cancer would help to clarify the
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mechanism underlying the interactions between cancer cells and
stromal cells, and may provide novel targets for stroma-directed
therapies.
CD271 (also known as nerve growth factor receptor, NGFR or
p75NTR) is a neurotrophin receptor that has been implicated in
the paracrine growth regulation of a number of neuronal and non-
neuronal tumor types [14,15]. Recent studies have focused on
CD271 because it was identified as a marker of human
mesenchymal stem cells [16] and it has been evaluated as an
important cancer stem cell marker in melanoma [17]. CD271
might be a marker of a specific functional subpopulation, such as
stemness. In the pancreas, CD271 expression in PSCs has been
detected [18]. However, CD271 expression rapidly decreased after
cell isolation from pancreatic tissues [19]. Therefore, the role of
CD271 expression in PSCs remains unclear.
The aim of this study was to identify the specific PSCs that affect
the progression of cancer cells by focusing on the expression of
CD271. We further assessed the significance of CD271 expression
in PSCs.
Materials and Methods
Ethics statement
The study was approved by the Ethics Committee of Kyushu
University (approval number, 23–64) and conducted according to
the Ethical Guidelines for Human Genome/Gene Research
enacted by the Japanese Government and the Helsinki Declara-
tion. All the patients provided signed informed consent approving
the use of their tissues for unspecified research purposes. For all
experiments involving mice, the animals were housed in laminar-
flow cabinets under specific pathogen-free conditions in facilities
approved by Kyushu University (approval number, A24-112-0).
Patients and pancreatic tissues
Pancreatic cancer tissues were obtained from 105 patients who
underwent pancreatic resection for pancreatic cancer at our
institution. The clinicopathologic characteristics of the patients are
described in Table S1. Survival was measured from the time of
pancreatic resection until death. Prognosis was determined in
September 2011. The median overall survival time was 23.5
months (range, 1–114 months). Sixty-two patients died during
follow-up. All tissues adjacent to the specimens were evaluated
histologically according to the criteria of the World Health
Organization. The tumor stage was assessed according to the
Union for International Cancer Control (UICC). We also
obtained 31 normal pancreas (NP) samples from intact pancreas
tissues resected for bile duct cancer, benign solid-pseudopapillary
tumor or neuroendocrine tumor for use as control tissues. We
further collected 10 pancreatic intraepithelial neoplasia (PanIN)
and 39 intraductal papillary mucinous neoplasm (IPMN) samples.
Immunohistochemical procedures and evaluation
Immunohistochemical staining was performed using a Histofine
SAB-PO Kit (Nichirei, Tokyo, Japan). Tissues were sectioned to a
thickness of 4 mm and were incubated with mouse monoclonal
anti-CD271 antibody (1:100; Santa Cruz Biotechnology, Santa
Cruz, CA) or mouse monoclonal anti-a-SMA antibody (1:50;
Dako, Glostrup, Denmark) overnight at 4uC. Cells were consid-
ered to be positively immunostained when the membrane or
cytoplasm was stained. We identified activated PSCs based on the
cell morphology (spindle-shaped cells) and their identities were
confirmed by a-SMA staining. We counted the number of cells in
at least 10 fields per section at 2006magnification. To account for
the heterogeneity in CD271 expression, the distribution of CD271
immunostaining was evaluated as percentages of the stained cells
and scored as follows: 0, 0%; 1, ,25%; 2, 26–50%; 3, 51–75%; or
4, 76–100%. Similarly, the staining intensity was scored as follows:
0, no staining; 1, weak staining; 2, moderate staining; or 3, strong
staining. Finally, we calculated the staining score by multiplying
the percentage score by the intensity score. In the pancreatic
cancer cells, we divided the samples into high staining .3 and low
staining ,2 groups. All slides were evaluated independently by
two investigators without any knowledge of the clinical features of
each case.
Cells and culture conditions
Human PSCs were isolated from fresh pancreatic surgical
specimens using the outgrowth method in our laboratory [5,20].
The PSC cell type was confirmed by morphology (stellate-like or
spindle-shaped cells) and by immunofluorescence staining for a-
SMA and vimentin [10,13,20]. PSC1 and PSC3-9 were isolated
from pancreatic cancer. PSC2 and PSC10 were isolated from
benign pancreatic cyst. PSC11 and PSC12 were isolated from
normal pancreatic area of pancreatic cancer tissues. In addition,
we evaluated two pancreatic cancer cell lines, SUIT-2 (Health
Science Research Resources Bank, Osaka, Japan) and Capan-2
(American Type Culture Collection, Manassas, VA). SK-N-MC, a
human neuroepithelioma cell line (American Type Culture
Collection), was purchased as a positive control for CD271
expression. Cells at passages 3 to 8 were used for assays. The cells
were maintained as previously described [21].
Immunofluorescence staining and Laser-Scanning
confocal microscopy
PSCs (16105) were plated on glass-bottom dishes (Matsunami,
Osaka, Japan) and incubated for 24 hours. In cultures with
supernatant, cells were incubated in 10% fetal bovine serum
(FBS)/DMEM with supernatant derived from pancreatic cancer
cells for 72 hours. The cells were then fixed with methanol,
blocked with 3% bovine serum albumin in phosphate-buffered
saline solution (PBS), and incubated with a mouse monoclonal
anti-a-SMA antibody (1:50; Dako), a rabbit monoclonal anti-
vimentin antibody (1:50; Cell Signaling Technology, Beverly, MA)
and a mouse monoclonal anti-CD271 antibody (1:50; Santa Cruz
Biotechnology) overnight at 4uC. Subsequently, the cells were
incubated with Alexa 488-conjugated anti-mouse IgG or 546-
conjugated anti-rabbit IgG (Molecular Probes, Eugene, OR) for
1 hour. Nuclear DNA was counterstained with 49,6-diamidino-2-
phenylindole (0.05 mg/mL). A laser-scanning confocal fluorescent
microscope (A1R; Nicon, Tokyo, Japan) was used, and images
were managed using NIS-Elements software (Nikon).
Flow cytometry analysis
Cultured cells were obtained from subconfluent monolayer
cultures and incubated with a fluorescein isothiocyanate (FITC)-
conjugated anti-CD271 antibody (Miltenyi Biotec, Auburn, CA).
Mouse IgG1 K Isotype Control FITC (Miltenyi Biotec) was used
as a negative control. The labeled cells were analyzed by flow
cytometry using a FACS Calibur (Becton Dickson and Company,
Franklin Lakes, NJ).
Real-time quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from cultured cells using a High Pure
RNA Isolation Kit (Roche Diagnostics, Mannheim, Germany) and
DNase I (Roche Diagnostics). Real-time qRT-PCR was performed
using a QuantiTect SYBR Green Reverse Transcription-PCR Kit
(Qiagen, Tokyo, Japan) and a Chromo4 Real-Time PCR
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Detection System (Bio-Rad Laboratories, Hercules, CA). Primers
for CD271 and b-actin were purchased from Takara Bio Inc.
(Tokyo, Japan). The sequences of the oligonucleotide primers used
in this study were as follows: CD271, 59-TCAGTGG-
CATGGCTCCAGTC-39 (forward) and 59-GCAGTATC-
CAGTCTCAGCCCAAG-39 (reverse); b-actin, 59-TGGCACC-
CAGCACAATGAA-39 (forward) and 59-CTAAGTCATAGTC-
CGCCTAGAAGCA-39 (reverse). Each reaction mixture was
initially incubated at 50uC for 30 min to allow reverse transcrip-
tion. PCR amplification was then initiated by incubation at 95uC
for 15 min to activate the polymerase, followed by 40 cycles of
95uC for 5 s, 60uC for 20 s, and 72uC for 30 s. The expression
levels of genes were calculated using a standard curve constructed
using total RNA from SK-N-MC cells. The expression levels were
normalized to the b-actin expression levels as an internal control,
and expressed as the ratio of expression of the target gene to that
of b-actin. All samples were run in triplicate. No detectable PCR
products were amplified without prior reverse transcription. The
accuracy and integrity of the PCR products were confirmed using
an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto,
CA).
In vitro coculture system
In vitro cocultures were performed using 6-well cell culture insert
companion plates and 3.0-mm cell culture inserts (Becton
Dickinson Labware, Franklin Lakes, NJ) as previously described
[22]. SUIT-2 and Capan-2 cells (56105) were seeded separately
into the upper chambers at 24 hours after seeding two types of
PSCs (56105) into the lower chambers.
Culture with a cancer cell-derived supernatant
SUIT-2 and Capan-2 cells were cultured under FBS-free
conditions for 48 hours. Thereafter, we collected the supernatants
from the cancer cells and adjusted them to 10% FBS. The cancer
cell-derived supernatants were then added to previously seeded
PSCs for subsequent culture.
Functional separation by Matrigel invasion assay
Six-well cell culture insert companion plates and 8.0-mm cell
culture inserts (Becton Dickinson Labware) were coated with
Matrigel (150 mg/well; BD Biosciences, Bedford, MA). PSCs
(56105 cells/2 mL) were seeded into the upper chambers.
Previously, cancer cells (56105) were seeded into the lower
chambers. Thereafter, the cells were cultured for 72 hours.
Subsequently, we removed the cells from both sides of the upper
chambers using trypsin. After two centrifugations, we extracted
mRNA from the cells. Each experiment was carried out in
triplicate wells, and independent experiments were repeated three
times.
In vivo experiments
SUIT-2 pancreatic cancer cells and two types of PSCs were
used for in vivo experiments. Cells were divided into three groups,
comprising SUIT-2 cells alone, SUIT-2 cells with PSC1 cells, and
SUIT-2 cells with PSC2 cells. SUIT-2 cells (56105) and PSCs
(56105) suspended in 100 mL of PBS were cotransplanted into the
pancreatic tail of 6-week-old female SCID mice (FOX CHASE
SCIDH, C.B-17/lcr-scid/scidJcl; Clea Japan Inc., Tokyo, Japan).
Six mice were used in each group. The tumors were resected on
days 8, 15, and 22 after implantation. The tissues were fixed in
10% neutral-buffered formalin and embedded in paraffin. Four
mm tissue sections were stained with a mouse monoclonal anti-a-
SMA antibody (Dako) and a rabbit monoclonal anti-CD271
antibody (Millipore, Billerica, MA).
Statistical analysis
Values are expressed as means 6 SD. Comparisons between
two groups were performed using Student’s t-test. Statistical
significance was defined as values of p,0.05. A x2 test was used to
analyze the correlations between CD271 expression and the
clinicopathologic characteristics observed in the immunohisto-
chemical analyses. Survival analyses were undertaken using the
Kaplan–Meier method, and the curves were compared using the
log-rank test. To evaluate independent prognostic factors associ-
ated with survival, a multivariate Cox proportional-hazards
regression analysis was used, with CD271 expression, pT category,
lymph node metastasis, UICC stage, perilymphatic invasion,
perivascular invasion, and pathological margin as covariates. All
statistical analyses were performed using JMP 8.0 software (SAS
Institute, Cary, NC).
Results
Stromal cells express CD271 in pancreatic ductal
adenocarcinoma (PDAC)
To evaluate CD271 expression in pancreatic tissues, we
performed immunohistochemistry for CD271. Consistent with a
previous report [23], we observed strong staining of nerves as a
positive control. The epithelial cells of normal pancreatic ducts
showed no expression of CD271, and PDAC cells were unstained.
In normal pancreas (NP), stromal cells around the pancreatic duct
were rarely stained (Figure 1A-a). However, we observed that
stromal cells were strongly stained around pancreatic intraepithe-
lial neoplasia (PanIN) (Figure 1A-b) and intraductal papillary
mucinous neoplasm (IPMN) (Figure 1A-c). In PDAC tumors,
stromal cells around pancreatic cancer cells were partly stained.
However, CD271+ stromal cells were not adjacent to cancer cells
in PDAC, and were strongly stained at the edge rather than the
center of the tumors (Figure 1A-d). CD271 high staining in stromal
cells was present in 6.5% (2/31) of NP, 30.0% (3/10) of PanIN,
27.6% (29/105) of PDAC and 84.6% (33/39) of IPMN. The
CD271 high staining rates were significantly higher in stromal cells
of IPMN (p,0.0001) and PDAC (p= 0.0069) than those in
stromal cells of NP (Table 1).
Stromal CD271 expression independently correlated with
good prognosis
We evaluated correlations between stromal CD271 expression
and the clinicopathologic factors of PDAC. Although differences
did not reach statistical significance, pT1/pT2, no lymph node
metastasis, UICC stage I, no perilymphatic invasion, no perivas-
cular invasion, and pathological margin/negative were observed
more frequently in the stromal CD271high staining group than in
the stromal CD271 low staining group (Table 2). Interestingly,
stromal CD271 expression was associated with a good prognosis in
pancreatic cancer (p = 0.0040) (Figure 1B). The median survival
times for CD271 high staining and CD271 low staining patients
were 62 and 18.5 months, respectively. Next, we performed a
multivariate survival analysis based on the Cox proportional
hazard model for all parameters found to be significant by
univariate analyses, including stromal CD271 expression, pT
category, lymph node metastasis, UICC stage, perilymphatic
invasion, perivascular invasion, and pathologic margin positivity
(Table S2). Stromal CD271 expression was found to be an
independent prognostic marker in pancreatic cancer patients, and
the relative risk of stromal CD271 expression was 0.495 (Table 3).
CD271+ Cells for Pancreatic Cancer Prognosis
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CD271 stromal cells are a subpopulation of activated
PSCs
To characterize the CD271+ stromal cells, we performed
immunohistochemistry for a-SMA, a marker for activated PSCs,
on serial PDAC sections. We found that a-SMA was expressed in
most stromal cells around cancer cells and neoplastic tubules
(Figure 1A-e). CD271+ stromal cells were restricted to areas with
strong a-SMA expression. These findings indicate that CD271+
stromal cells are a subpopulation of activated PSCs.
CD271 expression in human PSCs
We isolated five primary cultures of PSCs from fresh human
pancreatic tissues, and their identity was confirmed by immuno-
fluorescence staining. PSCs were stellate-like or spindle-shaped
and expressed a-SMA and vimentin (Figure 2A). In these
immunofluorescence analyses, we did not detect CD271 expres-
sion in PSCs (data not shown). Next, we evaluated CD271
expression in 12 primary cultures of human PSCs using flow
cytometry, and found CD271-positive rates of 0.0–2.1% in PSCs
(Figure 2B).
CD271+ PSCs are increased through cancer–stroma
interactions
We investigated the effects of PSCs on the phenotype of cancer
cells using a coculture system. We used two pancreatic cancer cell
lines, SUIT-2 and Capan-2, and two primary cultures of human
PSCs isolated from PDAC and benign pancreatic cysts. After
monoculture or coculture with pancreatic cancer cells for
72 hours, we evaluated CD271 expression in PSCs using flow
cytometry and real-time qRT-PCR. By flow cytometry analyses,
we observed the percentage of CD271+ cells was higher in
coculture than in monoculture (0.7% vs. 0.1%) (Figure 3A). By
real-time qRT-PCR analyses, the level of CD271 mRNA
expression in two cultures of PSCs was significantly higher in
coculture with pancreatic cancer cells than in the monoculture
(p,0.001) (Figure 3B). Next, we collected supernatant from SUIT-
Figure 1. Characterization of stromal CD271 expression in pancreatic cancer. (A) Immunohistochemical staining for CD271 in pancreatic
tissues. (A-a) In normal pancreas (NP), stromal cells rarely stain positive for CD271. (A-b, -c) Stromal cells are strongly stained around pancreatic
intraepithelial neoplasia (PanIN) (b) and intraductal papillary mucinous neoplasm (IPMN) (c). (A-d) In pancreatic ductal adenocarcinomas (PDAC),
stromal cells are partly stained, and CD271+ stromal cells are not adjacent to pancreatic cancer cells. Black arrowheads and arrows indicate CD271+
cells and nerves as positive control in the serial sections. (A-e) a-smooth muscle actin (SMA) is expressed most stromal cells around cancer cells and
neoplastic tubules. White arrowheads indicate a-SMA cells in the serial sections. Original magnification: 2006, insets: 6006. (B) Kaplan–Meier survival
analysis for CD271 high expression in the stroma of PDAC. Stromal CD271 high expression is associated with a good prognosis (p = 0.0040).
doi:10.1371/journal.pone.0052682.g001
Table 1. Stromal CD271 high staining rates in surgical
pancreatic tissues.
Diagnosis High staining rates p value
NP 6.5% (2/31) -
PanIN 30.0% (3/10) 0.0669
PDAC 27.6% (29/105) 0.0069
IPMN 84.6% (33/39) ,0.0001
NP: normal pancreas; PanIN: pancreatic intraepithelial neoplasia; PDAC:
pancreatic ductal adenocarcinoma; IPMN: intraductal papillary mucinous
neoplasm. Comparisons between NP and the three tumor groups were
determined.
doi:10.1371/journal.pone.0052682.t001
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2 pancreatic cancer cells, and added it to two primary cultures of
PSCs. We compared the levels of CD271 mRNA expression
among monocultures, cultures with the cancer cell-derived
supernatant, and cocultures with pancreatic cancer cells for
72 hours. The level of CD271 mRNA expression was highest in
cocultures with pancreatic cancer cells. In addition, the level of
CD271 mRNA expression was higher in cultures with the cancer
cell-derived supernatant than in monocultures (p = 0.0053)
(Figure 3C). By immunofluorescence analyses, we detected
CD271 expression in PSCs was slightly increased in culture with
the cancer cell-derived supernatant in contrast to monocultures
(Figure 3D).
CD271 expression decreases after the transient increase
in expression when cocultured with pancreatic cancer
cells
We used a coculture system consisting of two pancreatic cancer
cell lines, SUIT-2 and Capan-2, and two primary cultures of
human PSCs to evaluate the time-dependent changes in CD271
mRNA expression. After monoculture or coculture of PSCs with
pancreatic cancer cells for 1 to 5 days, we evaluated the level of
CD271 mRNA expression in PSCs. In monocultures, the
expression of CD271 mRNA in PSCs did not change. However,
in cocultures with pancreatic cancer cells, the level of CD271
mRNA expression increased on day 3 (p = 0.0249) and peaked at
day 4 (p,0.0001). Interestingly, the levels of CD271 mRNA
expression decreased the day after peak expression (p,0.0001)
(Figure 4A). Next, we collected supernatant from Capan-2
pancreatic cancer cells, added it to two primary cultures of PSCs
and evaluated the time-dependent changes in CD271 mRNA
expression. In cultures with supernatant, the level of CD271
mRNA expression increased on day 2 (p,0.0001) and then
decreased on day 4 (p,0.0001) (Figure 4B). Similar to coculture
with pancreatic cancer cells, CD271 expression decreased after the
transient increase in expression when cocultured with supernatant.
Table 2. Relationships between stromal CD271 expression and clinicopathologic factors.
CD271 low staining CD271 high staining
Characteristics n =76 (72.4%) n=29 (27.6%) p Value
Age ,65 35 (46.1) 16 (55.2) 0.403
$65 41 (54.0) 13 (44.8)
pT category pT1/pT2 7 (9.21) 7 (24.1) 0.055
pT3/pT4 69 (90.8) 22 (75.9)
Histologic grade G1 9 (11.8) 4 (13.8) 0.564
G2 24 (31.6) 13 (44.8)
G3 39 (51..3) 11 (37.9)
others 4 (5.3) 1 (3.5)
Lymph node metastasis No 17 (22.4) 12 (41.4) 0.057
Yes 59 (77.6) 17 (58.6)
UICC stage I 5 (6.58) 6 (20.7) 0.128
II 69 (90.8) 22 (75.9)
III/IV 2 (2.63) 1 (3.45)
Perilymphatic invasion No 18 (23.7) 12 (41.4) 0.079
Yes 58 (76.3) 17 (58.6)
Perivascular invasion No 28 (36.8) 16 (55.2) 0.09
Yes 48 (63.2) 13 (44.8)
Perineural invasion No 14 (18.4) 5 (17.2) 0.888
Yes 62 (81.6) 24 (82.8)
Pathological margin Negative 50 (65.8) 25 (86.2) 0.082
Positive 26 (34.2) 4 (13.8)
UICC, Union for International Cancer Control.
Table 3. Multivariate survival analysis (Cox regression model)
of conventional prognostic factors and stromal CD271
expression.
Relative risk
95% Confidence
interval p value
CD271 positivity 0.495 0.231–0.962 0.0349
pT category 7.621 1.179–28.117 0.0361
Lymph node metastasis 1.864 0.860–4.658 0.1194
UICC stage - - 0.0229
Perilymphatic invasion 1.188 0.509–1.966 0.6751
Perivascular invasion 1.908 1.074–3.717 0.0276
Pathological margin 6.433 0.668–62.02 0.0006
The relative risk of the UICC stage is not shown because it is comprised of two
parameters.
UICC, Union for International Cancer Control.
doi:10.1371/journal.pone.0052682.t003
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CD271 expression is decreased in PSCs migrating
through Matrigel toward pancreatic cancer cells
Next, we evaluated CD271 expression in PSCs after functional
separation using Matrigel invasion assay. In this culture system
involving upper chambers coated with Matrigel, we evaluated
SUIT-2 pancreatic cancer cells and two primary cultures of
human PSCs. PSCs in the upper chambers were incubated for
72 hours in culture with pancreatic cancer cells in the lower
chambers, or as controls without pancreatic cancer cells in the
lower chambers. PSCs were collected from the top and bottom
sides of the upper chambers separately. The top side-derived PSCs
were cells that did not migrate toward the cancer cells through the
Matrigel and remained in the upper chambers. The bottom side-
derived PSCs were cells that migrated toward the pancreatic
cancer cells through Matrigel and collected on the bottom side of
the upper chambers. We then analyzed CD271 mRNA expression
levels in the top or bottom side-derived PSCs to evaluate the
functional differences between CD271+ and CD2712 PSCs. The
level of CD271 mRNA expression was highest in top side-derived
PSCs after culture with pancreatic cancer cells (p,0.001).
Interestingly, the level of CD271 mRNA expression in the bottom
side-derived PSCs migrating toward the pancreatic cancer cells
was lower than that in the top side-derived PSCs that did not move
toward cancer cells (p,0.01). In controls, there were no
differences in CD271 mRNA expression levels between top and
bottom side-derived PSCs, and these levels were low compared
with the levels of CD271 mRNA expression in cultures with
pancreatic cancer cells (Figure 4C).
CD271+ PSCs are present in tumor margins/periphery
and are absent in the tumor core
To evaluate the localization of CD271+ PSCs in vivo, we
transplanted SUIT-2 pancreatic cancer cells into the pancreatic
tail of SCID mice, or cotransplanted them with two primary
cultures of human PSCs. We euthanized the mice on days 8, 15, or
22, and evaluated the localization of CD271+ PSCs in the
xenograft tumors. Stromal CD271 expression was detected at all
days after transplantation, regardless of transplantation or
cotransplantation. Stromal CD271 high staining rates were 50%
(3/6), 60% (3/5), and 67% (4/6) on days 8, 15, and 22,
respectively. In every case, we detected CD271 expression on
nerve bundles as a positive control, and found that pancreatic
cancer cells never expressed CD271. We confirmed the presence
of activated PSCs by a spindle-shaped morphology and by a-SMA
staining. Activated PSCs existed in the xenograft tumors and
normal pancreatic areas around the tumors (Figure 5A). However,
CD271+ PSCs only existed in the normal pancreatic areas around
the xenograft tumors, and were absent in the tumor core
(Figure 5B).
Discussion
Previously, Trim et al., [18] reported that CD271 was expressed
in PSCs. Haas et al., [19] also reported that CD271 was slightly
expressed in PSCs and that the level of CD271 mRNA expression
rapidly decreased in primary rat PSCs during culture. We found
that CD271+ PSCs existed in surgical pancreatic tissues using
immunohistochemistry. However, qRT-PCR and flow cytometry
analyses revealed that CD271 expression in PSCs isolated from
pancreatic tissues was very weak. These findings suggest that
CD271 expression in primary human PSCs also rapidly decreased
during culture.
We found that CD271 mRNA expression was transiently
increased in PSCs cocultured with pancreatic cancer cells,
suggesting that pancreatic cancer cells enhance CD271 expression
in PSCs. However, the present immunohistochemical analyses
revealed that CD271+ PSCs also existed around PanIN and
IPMN, precancerous lesions. Furthermore, Trim et al., [18]
reported that CD271+ PSCs were found in tissues from chronic
pancreatitis patients. These observations suggest the appearance of
CD271+ PSCs is not specific to malignant diseases, and is related
Figure 2. Analyses of CD271 expression in human pancreatic stellate cells (PSCs) isolated from pancreatic tissues. (A) Representative
microphotograph of immunofluorescence staining for a-smooth muscle actin (SMA) (green) and vimentin (red) in PSCs. Nuclei were counterstained
with 49,6-diamidino-2-phenylindole (blue). PSCs show a stellate-like or spindle-shaped morphology and express a-SMA. Original magnification: 2006.
(B) The positive rates of CD271 expression in PSCs are 0.0–2.1% by flow cytometric analyses. Representative flow cytometric images of CD271 in
activated PSCs are also shown (right).
doi:10.1371/journal.pone.0052682.g002
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to desmoplasia. Haas et al., [19] reported that CD271 mRNA
expression was enhanced in PSCs by transforming growth factor
beta (TGFb), a strong profibrogenic activator of PSCs. Addition of
TGFb to PSCs slightly increased the level of CD271 mRNA
expression in PSCs, but without a significant difference (data not
shown). Although TGFb secreted from pancreatic cancer cells
may be related to CD271 expression in PSCs, it is possible that
other soluble factors also affect CD271 expression.
Interestingly, CD271+ stromal cells were not adjacent to
pancreatic cancer cells in PDAC as observed by immunohisto-
chemical analyses. In vivo, CD271 expression decreased after the
transient increase in expression in PSCs cocultured with pancre-
atic cancer cells. These findings suggest that CD271 expression is
decreased in PSCs following long-term interactions with pancre-
atic cancer cells. In pancreatic cancer tissues, CD271 high staining
cases have a better prognosis than CD271 low staining cases.
Progression of PDAC may cause the decrease of CD271 positive
rate of PSCs due to the long-term influences of pancreatic cancer
cells.
The functional role of CD271+ PSCs remains unclear. Previous
reports identified CD271 as a marker of activated PSCs [18,19].
However, CD271 expression in PSCs rapidly decreased during
primary culture [19], even though a-SMA expression in PSCs
remained after several passages of primary cultures. Recently,
several articles have reported that normal fibroblasts, which
prevented tumor growth and invasiveness, became reprogrammed
by unknown mechanisms to co-evolve with epithelial tumor cells
and provide an environment conducive to tumor initiation and
progression [24–28]. CD271 expression may be a marker for such
a reprogramming stage, suggesting that CD271 expression is a
temporary marker of PSCs in the early stages of interaction with
pancreatic cancer cells. Previously, we reported that CD10+ PSCs
enhanced the malignant progression of pancreatic cancer [13].
CD10+ PSCs existed near pancreatic cancer cells, and the
existence of CD10+ PSCs suggested a poor prognosis. In the
present study, we found that CD10 mRNA expression continu-
ously increased in cocultures with pancreatic cancer cells but did
not decrease in PSCs migrating through Matrigel toward
pancreatic cancer cells (data not shown). In contrast, CD271+
PSCs existed near pancreatic tumors, but were separate from
pancreatic cancer cells, rather than adjacent, and the existence of
CD271+ PSCs was an independent factor for good prognosis.
These findings suggest that CD271+ PSCs may play a defensive
role in pancreatic carcinogenesis and/or progression of pancreatic
Figure 3. CD271+ pancreatic stellate cells (PSCs) are increased through cancer–stroma interactions. (A) In flow cytometry analyses, the
percentage of CD271+ cells is higher in coculture than in monoculture (0.7–0.8% vs. 0.1%). (B) The levels of CD271 mRNA expression in two cultures of
PSCs are significantly higher in cocultures with pancreatic cancer cells than in monocultures (p,0.001). (C) The level of CD271 mRNA expression is
higher in cultures with a cancer cell-derived supernatant than in monocultures (p = 0.0053). (D) Representative microphotograph of
immunofluorescence staining for CD271 (green) and a-smooth muscle actin (SMA) (red) in PSCs. Nuclei were counterstained with 49,6-diamidino-
2-phenylindole (blue). CD271 in PSCs was slightly expressed in cultures with cancer cell-derived supernatant, although it was difficult to detect CD271
expression in monocultures. Original magnification: 2006. *p,0.01; **p,0.001.
doi:10.1371/journal.pone.0052682.g003
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Figure 4. CD271 expression in pancreatic stellate cells (PSCs) decreases after long-term interactions with pancreatic cancer cells. (A)
Real-time qRT-PCR analyses showed that the levels of CD271 mRNA expression in PSCs in coculture with pancreatic cancer cells start to increase on
day 3 (p = 0.0249), are highest on day 4 (p,0.0001), and then decrease the following day after the peak expression (p,0.0001). (B) In cultures with
addition of cancer cell-derived supernatant, the level of CD271 mRNA expression started to increase at day 2 (p,0.0001) and then decreased on day 4
(p,0.0001). (C) Evaluation of the differences in CD271 expression depending on the function of PSCs by real-time qRT-PCR. The level of CD271 mRNA
expression in top side-derived PSCs, which did not move toward cancer cells through Matrigel and remained on upper chambers, is lower than that
in bottom side-derived PSCs, which did move toward pancreatic cancer cells through Matrigel (p,0.01). *p,0.05; **p,0.01; ***p,0.001; NS, not
significant.
doi:10.1371/journal.pone.0052682.g004
Figure 5. Expression of a-smooth muscle actin (SMA)+ and CD271+ stromal cells during in vivo tumor growth of pancreatic cancer.
(A) a-SMA+ stromal cells, as activated PSCs, exist in the xenograft tumor and normal pancreas (NP) areas (left side) around the tumor (right side). (B)
Few CD271+ stromal cells were present in the NP area (left side) around the xenograft tumor, and were absent in the tumor core (right side). Original
magnification: 2006.
doi:10.1371/journal.pone.0052682.g005
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cancer, and that long-term interactions with cancer cells may
reduce the number of CD271+ PSCs. However, CD271+ PSCs
were too difficult to isolate after primary cultures. Therefore, we
were unable to evaluate directly the function of CD271+ PSCs,
and further investigations are required.
In conclusion, CD271+ PSCs existed near pancreatic cancer
tumors, and CD271 expression correlated with a better prognosis of
human pancreatic cancer. A short interaction with cancer cells
transiently increased the expression of CD271 in PSCs, while a long
interaction with cancer cells decreased CD271 expression in PSCs.
CD271+ PSCs appeared during the early stages of cancer–stroma
interactions. Taken together, the present findings suggest that the
CD271+ subpopulation of PSCs may play a role in the resistance to
pancreatic carcinogenesis and progression of pancreatic cancer.
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